Synonym
IX 207-887; 10-Mbctya; IX 207,887
IUPAC/Chemical Name
(10-Methoxy-4H-benzo(4,5)cyclohepta(1,2-b)thien-4-ylidene)acetic acid
InChi Key
XIKRQPKFOKKGGW-LCYFTJDESA-N
InChi Code
InChI=1S/C16H12O3S/c1-19-14-8-10-4-2-3-5-11(10)13(9-15(17)18)12-6-7-20-16(12)14/h2-9H,1H3,(H,17,18)/b13-9-
SMILES Code
O=C(O)/C=C1C2=CC=CC=C2C=C(OC)C3=C/1C=CS3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
284.33
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Schnyder J, Bollinger P, Payne TG. Inhibition of monokine release by IX 207-887. Agents Actions. 1990 Jan;29(1-2):108-10. PubMed PMID: 2327310.
2: Mackenzie AR, Bollinger P, Cooper PH, Del Pozo E, Elford P, Graeber M, Gubler HU, Leutwiler A, Payne T, Ruch W, et al. Pharmacological effects of a new antiarthritic agent, IX 207-887. Br J Rheumatol. 1991;30 Suppl 2:75-8. PubMed PMID: 1899626.
3: Schnyder J, Cooper P, MacKenzie A. Modulation of secretory processes of phagocytes by IX 207-887. Springer Semin Immunopathol. 1993;14(4):345-52. PubMed PMID: 8322166.
4: Schnyder J, Bollinger P, Payne T. Inhibition of interleukin-1 release by IX 207-887. Agents Actions. 1990 Jun;30(3-4):350-62. PubMed PMID: 2386108.
5: Dougados M, Combe B, Beveridge T, Bourdeix I, Lallemand A, Amor B, Sany J. IX 207-887 in rheumatoid arthritis. A double-blind placebo-controlled study. Arthritis Rheum. 1992 Sep;35(9):999-1006. PubMed PMID: 1418029.
6: Rainsford KD, Ying C, Smith F. Selective effects of some 5-lipoxygenase inhibitors on synovial interleukin-1 (IL-1) production compared with IL-1 synthesis inhibitors. Agents Actions. 1993;39 Spec No:C186-8. PubMed PMID: 8273563.
7: Török K, Németh K, Erdö F, Arányi P, Székely JI. Measurement and drug induced modulation of interleukin-1 level during zymosan peritonitis in mice. Inflamm Res. 1995 Jun;44(6):248-52. PubMed PMID: 7583520.
8: Schuerer-Maly CC, Emmenegger U, Ott K, Flogerzi B, Halter F. Interleukin-1 and experimental gastric ulcer healing in the rat. J Physiol Pharmacol. 1993 Mar;44(1):23-9. PubMed PMID: 8518422.
9: Rainsford KD, Ying C, Smith F. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors. J Pharm Pharmacol. 1996 Jan;48(1):46-52. PubMed PMID: 8722494.
10: Seibel MJ, Brückle W, Respondek M, Beveridge T, Schnyder J, Müller W. [Initial clinical experiences in the treatment of chronic polyarthritis with a new monokine release inhibitor]. Z Rheumatol. 1989 May-Jun;48(3):147-51. German. PubMed PMID: 2675492.
